Erythropoiesis-Stimulating Agent Use Among Non–Dialysis-Dependent CKD Patients Before and After the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Using a Large US Health Plan Database
Conclusions TREAT appears to be a watershed study that was followed by a marked decline in ESA prescribing for patients with CKD.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Anemia | Aranesp | Cardiology | Cardiovascular | Chronic Kidney Disease | Databases & Libraries | Dialysis | Heart | Study | Urology & Nephrology